Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombotic Disorder Clear all
Completed Not applicable Interventional Accepts healthy volunteers

PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

NCT02997111
View directory record Official record
Conditions
Platelet Function, Thrombosis
Interventions
PFA-100
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Treatment Trial for Post-Thrombotic Syndrome

NCT00633971
View directory record Official record
Conditions
Post Thrombotic Syndrome
Interventions
complex lymphedema therapy
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 26, 2026, 9:20 PM EDT
Not listed Phase 4 Interventional

Post Intravitreal Injection Topical NSAID vs. Patching

NCT03918590
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
Drug · Other
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 3 Interventional

Crux Biomedical Vena Cava Filter Study - United States

NCT01120509
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Inferior Vena Cava Filter
Device
Lead sponsor
Crux Biomedical
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Orange, California • Sacramento, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 26, 2026, 9:20 PM EDT
Terminated Not applicable Interventional Results available

SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines

NCT01670188
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Pneumatic SCD - VenaFlow System (DJO Global)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 26, 2026, 9:20 PM EDT
Completed No phase listed Observational

A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).

NCT07732361
View directory record Official record
Conditions
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
4 Weeks and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Akron, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 26, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083
View directory record Official record
Conditions
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Interventions
Biological: narsoplimab
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
28 Days to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
San Diego, California • Gainesville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Duration of Therapy for Thrombosis in Children

NCT00687882
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention
Other
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery

NCT01976988
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Heparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Sep 26, 2026, 9:20 PM EDT
Completed No phase listed Observational

A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters

NCT00001518
View directory record Official record
Conditions
Catheters, Indwelling, Thrombosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

NCT00422396
View directory record Official record
Conditions
Hypertriglyceridemia With the Metabolic Syndrome
Interventions
Fenofibrate (drug)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 26, 2026, 9:20 PM EDT
Active, not recruiting Phase 4 Interventional

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulation with heparin, EkoSonicTM Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional

Point of Care Testing to Improve Monitoring of LVAD Patients

NCT03555552
View directory record Official record
Conditions
Anticoagulation and Thrombosis Point of Care Test (AT-POCT)
Interventions
Anticoagulation and Thrombosis Point of Care Test(AT-POCT), Duke Central Automated Laboratory (DCAL)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin in a Non-Diabetic Patient Population

NCT03772964
View directory record Official record
Conditions
Inflammatory Response
Interventions
MetFORMIN Hydrochloride ER, Placebo
Drug
Lead sponsor
Brian Zuckerbraun
Other
Eligibility
55 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

NCT03251963
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Surgery
Interventions
Fixed Dose Enoxaparin, Variable Dose Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Transcranial Magnetic Stimulation in Children With Stroke

NCT01637129
View directory record Official record
Conditions
Hemiparesis, Neonatal Stroke, Ischemic Stroke, Hemorrhagic Stroke, Thrombotic Stroke
Interventions
Transcranial Magnetic Stimulation, Sham Magnetic Stimulation
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 26, 2026, 9:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 26, 2026, 9:20 PM EDT
Not yet recruiting Not applicable Interventional

Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study

NCT07647939
View directory record Official record
Conditions
Atrial Fibrillation (AF), Pulmonary Embolism (PE), Left Atrial Appendage Thrombosis
Interventions
Delayed Un-gated CT Scan for Left Atrial Appendage Thrombus, Delayed Gated CT Scan for Left Atrial Appendage Thrombus
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 9:20 PM EDT
Withdrawn Phase 4 Interventional

Early Intrapleural TPA Instillation Versus Late

NCT03167281
View directory record Official record
Conditions
Tissue Plasminogen Activator
Interventions
early tPA and DNase
Combination Product
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 26, 2026, 9:20 PM EDT